News
Find out all the latest news and information on DHDDS here

Cure DHDDS and Cure DHDDS USA founders feature in Global Genes rare advocacy exchange
You can read the the full article here

Cure DHDDS & Cure DHDDS USA to sign second year contract with Mount Sinai Hospital to continue brain organoid investigations.

Cure DHDDS work with The READY Center at UCSF

Cardiff University identify possible theraputic option for DHDDS patients

Jackson Labs create partially humanised mutation mouse model.

Fuel It Still - by Ethan O. Perlstein, Ph.D.

3rd International Scientific Exchange Meeting - October 2024

Charlie Dixon’s cycle to raise funds for Cure DHDDS features in the ITV news

Cure DHDDS Win Award for Excellence in Medical Affairs-Led Scientific Exchange

DHDDS Founder Speaks at ORPHAN DRUGS & RARE DISEASES GLOBAL CONGRESS 2024

Cure DHDDS in the Press!

Founders of Cure DHDDS USA Share interviewed for WLKY News

Perlara Drug Repurposing screen update

Cure DHDDS Virtual Conference: Summary Report

Mel Dixon to speak at Festival of Genomics in 2024

Medical Podcast features DHDDS parents & advocates from Portugal.

First DHDDS Virtual Conference - September 2023
Cure DHDDS features in SW Londoner

Launch of Cure DHDDS USA
We have been working with Zoe and John for some months now developing research opportunities and building on our network of scientific experts. Together we are stronger and can work faster to find a treatment for these ultra rare mutations.

New contract signed for research in Montreal

Perlara drug repurposing contract signed

Cure DHDDS Raise awareness on American TV
Cure DHDDS on ITV London Tonight

Cure DHDDS Patron on Channel 4
Mel Dixon speaks at Beacons Conference 2023

Cure DHDDS Proud to reveal new short film
Produced by: Cine Schools

Biotin as a new therapeutic approach?
Publication: Molecular Genetics and Metabolism

EpiSignature Study into DHDDS Gene Mutation
EpiSignature is a study of genomic DNA methylation patterns (beyond the coding sequences) to differentiate patients with similar or different phenotypes and genetic changes at the DNA coding level.
Genetic changes in the DHDDS gene have been found in some cases to be associated with a progressive course, while in other cases a static course. EpiSignature tries to determine whether there is any significant difference in methylation pattern that could account for such difference, thus potentially providing some insight for progression and prognosis.
Charity founders in South East Genomics article
Cure DHDDS founders Mel and Charlie Dixon feature in South East Genomics article discussing the struggles and opportunities that come with an ultra rare genetic diagnosis.